Safety and tolerability of intermittent androgen deprivation therapy: A literature review

Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health Among Men with Prostate Cancer

(2017) Philip J. Saylor et al.   Journal of the National Comprehensive Cancer Network

Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

(2010) Glenn N. Levine et al.   CIRCULATION

Degarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer

(2010) Michael Steinberg   CLINICAL THERAPEUTICS

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

(2010) Stacy Elliott et al.   Journal of Sexual Medicine

Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer

(2009) Roger S. Kirby et al.   BJU INTERNATIONAL

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

(2009) Fernando E.C. Calais da Silva et al.   EUROPEAN UROLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

44 INTERMITTENT VERSUS CONTINUOUS MAXIMAL ANDROGEN BLOCKADE IN METASTATIC (D2) PROSTATE CANCER PATIENTS. A RANDOMIZED TRIAL

(2009) N. Mottet et al.   EUROPEAN UROLOGY SUPPLEMENTS

Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes

(2009) Shabbir M.H. Alibhai et al.   JOURNAL OF CLINICAL ONCOLOGY

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer

(2009) N. L. Keating et al.   JNCI-Journal of the National Cancer Institute

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer

(2008) Matthew R. Smith et al.   CANCER

Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer

(2008) Nicholas Bruchovsky et al.   Clinical Genitourinary Cancer

INTERMITTENT ANDROGEN SUPPRESSION IN PATIENTS WITH ADVANCED PROSTATE CANCER: AN UPDATE OF THE TULP SURVIVAL DATA

(2008) J.F. Langenhuijsen et al.   EUROPEAN UROLOGY SUPPLEMENTS

EVALUATION OF QUALITY OF LIFE, SIDE EFFECTS AND DURATION OF THERAPY IN A PHASE 3 STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION

(2008) F.E. Calais Da Silva et al.   EUROPEAN UROLOGY SUPPLEMENTS